Reuters logo
BRIEF-Regeneron Provides Update On Eylea (Aflibercept) Injection And Nesvacumab (Ang2 Antibody) Combination Program
November 27, 2017 / 7:12 AM / 21 days ago

BRIEF-Regeneron Provides Update On Eylea (Aflibercept) Injection And Nesvacumab (Ang2 Antibody) Combination Program

Nov 27 (Reuters) - Regeneron Pharmaceuticals Inc:

* REGENERON PROVIDES UPDATE ON EYLEA® (AFLIBERCEPT) INJECTION AND NESVACUMAB (ANG2 ANTIBODY) COMBINATION PROGRAM

* REGENERON PHARMACEUTICALS INC -‍ RESULTS FROM TWO PHASE 2 STUDIES DID NOT PROVIDE SUFFICIENT DIFFERENTIATION TO WARRANT PHASE 3 DEVELOPMENT​

* REGENERON PHARMACEUTICALS - ‍RESULTS FROM RUBY, ONYX WILL BE FURTHER ANALYZED AND WILL BE SUBMITTED FOR PRESENTATION AT A FUTURE MEDICAL CONGRESS​

* REGENERON PHARMACEUTICALS - ‍EYLEA RESULTS CONSISTENT WITH FINDINGS IN PREVIOUS CLINICAL STUDIES; THERE WERE NO NEW SAFETY SIGNALS IN THESE STUDIES​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below